KALV · KalVista Pharmaceuticals, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on KALV. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About KALV · KalVista Pharmaceuticals Inc
As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
Live Quote
HOLD (score +3) · 12-1 mom 129.1% · RSI 76 · above_both · 0.0% from high
Targets blend Wall Street consensus (3 analysts: low $27.00 / mean $27.00 / high $27.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
KalVista is an approved rare-disease biotech with one commercial drug (EKTERLY/sebetralstat — first oral on-demand therapy for hereditary angioedema) that signed a definitive merger agreement with Italy's Chiesi Group on April 29, 2026 at $27.00/share in cash. The stock surged from ~$19 to $26.70 the day of announcement and has been anchored there since (currently $26.81, just $0.19 below deal price). The pending deal means options IV is suppressed and directional exposure is capped — the market treats this as a near-term binary event with expected closing in Q3 2026 subject to HSR/antitrust clearance. Insider Form 4 cluster was NOT open-market buying; it was routine RSU vestment (M code) with sell-to-cover tax withholdings across five executives over two weeks in May — zero discretionary P-code purchases. No mispricing exists: stock at $26.81 vs. deal price of $27.00 implies ~0.7% upside and a material downside scenario if the deal breaks.